Why the study?
Does UR-4501 (active metabolite of ticlopidine) inhibit platelet aggregation in vitro compared to 2-oxo-ticlopidine?
Does UR-4501 (active metabolite of ticlopidine) inhibit platelet aggregation in vitro compared to 2-oxo-ticlopidine?
UR-4501 was identified as the active metabolite of ticlopidine responsible for its in vivo anti-platelet activities.
May inform ticlopidine mechanism in vitro; leaves open clinical relevance pending in vivo validation.
1 Ticlopidine is a well-known anti-platelet agent, but is not active by itself in vitro. We identified a metabolite with anti-platelet activity, which was generated after incubation of 2-oxo-ticlopidine with phenobarbital-induced rat liver homogenate in vitro. 2 An active moiety (UR-4501) was isolated by high-performance liquid chromatography after large-scale preparation of metabolites. 3 The chemical structure of UR-4501 was determined by a combination of liquid chromatography mass/mass spectrometry (LC/MS/MS) and nuclear magnetic resonance (NMR) analysis. 4 UR-4501 produced a concentration-dependent inhibition (3-100 microm) of ADP (10 microm)-induced human platelet aggregation, whereas 2-oxo-ticlopidine (3-100 microm) did not elicit inhibitory responses. 5 UR-4501 (10-100 microm) strongly inhibited ADP- and collagen-induced aggregation and slightly inhibited thrombin-induced aggregation. 6 The inhibition of rat washed platelet aggregation by UR-4501 (100 microm) persisted, even after the platelets had been washed twice. 7 These results suggest that UR-4501 is the molecule responsible for the in vivo activities of ticlopidine.
No takes yet. Share an insight, caveat, or question.
Yoneda et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: